Every intervention Outliyr has scored for neuroplasticity, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for neuroplasticity; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
34 of 78 evaluated interventions score 3.0+ out of 10 for neuroplasticity · 7 comparisons
For neuroplasticity, Neurofeedback lands at 8.3/10 because Ostinelli et al. 2025 supports the core mechanism. Neurofeedback directly trains learned self-regulation of brain activity. Sitaram 2017 describes closed-loop brain training as a neuroplasticity…
Read the Neurofeedback report →Chronic stroke, TBI, and cognitive-aging studies repeatedly invoke perfusion and neuroplasticity signals. Efrati 2013 reports neurological improvement with brain perfusion changes in chronic post-stroke patients. Score above neutral with the caveat that…
Read the Hyperbaric Oxygen Therapy report →Zone 2 Cardio's 6.0/10 neuroplasticity score starts with Kodama 2009, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Aerobic exercise supports BDNF and vascular mechanisms…
Read the Zone 2 Cardio report →Lion's Mane neuroplasticity earns 6.0/10 because Willis 2025 anchors the most relevant signal. Lion's Mane fits neuroplasticity when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling…
Read the Lion’s Mane report →The neuroplasticity score is 6.0/10, and Semax needs careful framing. The neuroplasticity score rests on Dolotov et al. 2006, which found BDNF and TrkB upregulation in rat hippocampus after intranasal Semax, not…
Read the Semax report →A 5.8/10 for neuroplasticity fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Filip 2007 supports direction more than certainty. The existing rationale points to this narrower claim: JmjC histone-demethylase cofactor biology is neuroplasticity-adjacent, and this…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Glycine neuroplasticity earns 5.5/10 because Soh 2024 anchors the most relevant signal. Glycine fits neuroplasticity because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The…
Read the Glycine report →The use-case score for Whole-Body Vibration and neuroplasticity is 5.5/10, reflecting modest functional data in clinical cohorts Wang 2024. Whole-Body Vibration may promote proprioceptive re-patterning and sensory input that support rehabilitation learning,…
Read the Whole-Body Vibration report →The umbrella review by Poon et al. 2024 found that high-intensity interval protocols raise circulating BDNF, a factor linked to neuroplasticity, in about half of the examined studies. In the Norwegian 4x4…
Read the Norwegian 4×4 report →Population fit explains the 5.0/10 neuroplasticity score for Saffron because the evidence points to a plausible use case without proving a universal response. Zhang et al. 2025 is the best anchor here…
Read the Saffron report →The evidence does not support Metformin as a neuroplasticity enhancer, and no human studies have measured brain-training outcomes (see the null findings in the exercise-focused trial by Konopka 2019). Metformin's interaction with…
Read the Metformin report →Neuroplasticity stays 5.0/10 because Semaglutide has plausible GLP-1 brain mechanisms but no conclusive human neuroplasticity endpoint in this report. Yao 2024 supports metabolic effects, which may create a better environment for the…
Read the Semaglutide report →Dihexa neuroplasticity earns 5.0/10 because McCoy 2013 anchors the most relevant signal. Dihexa fits neuroplasticity only as a research-chemical hypothesis around synaptogenesis and memory circuits, not as a proven human nootropic. The…
Read the Dihexa report →Mechanistic mTOR and autophagy links are plausible, but human neurological effects were not significant in the systematic review.
Read the Rapamycin report →RF training may enhance prefrontal-autonomic coupling; thin direct human data.
Read the HRV Biofeedback report →No direct neuroplasticity endpoint was verified. EAAs support tissue protein synthesis generally but are not a targeted BDNF, learning, or synaptic-plasticity intervention.
Read the Essential Amino Acids report →Mechanistic support is reasonable. Hippocampal D1/D5-dependent LTP transformation (Mikhaylova/Behnisch 2007) and BDNF + NGF mRNA induction in striatum, hypothalamus, and hippocampus (Salimgareeva 2012) point to a plasticity-supporting profile. No human imaging or…
Read the Bromantane (Ladasten) report →Intense intervals can raise circulating BDNF and open short plasticity windows, but translation to durable learning gains is unproven for sprint protocols and varies widely between people.
Read the Sprinting (Sprint Interval Training) report →Neuroplasticity remains exploratory. GHK-related neuroprotection and VEGFA pathway signals exist in animal work, including Zhang 2018, but no human neuroplasticity endpoint trial exists for GHK-Cu.
Read the GHK-Cu report →PS supports PKC-mediated membrane signaling and synaptic function, with clinical support only indirectly through memory trials. This is relevant but not a direct neuroplasticity endpoint.
Read the Phosphatidylserine report →Neuroplasticity is mostly preclinical and cognition-adjacent. Withanolide biology supports neuronal-growth hypotheses, and Zhu 2026 improves the adult cognition evidence base. Direct human brain-imaging or structural neuroplasticity trials remain absent.
Read the Ashwagandha report →IGF-1 supports synaptic plasticity and brain repair pathways, and Baker 2012 gives a human cognition signal. Direct tesamorelin neuroplasticity biomarkers remain sparse.
Read the Tesamorelin report →No human tirzepatide neuroplasticity endpoint is verified. Incretin pathways have neurobiological plausibility. Obesity and diabetes trials do not prove neuroplasticity enhancement. Keep below neutral and resist mechanistic over claims (Drucker 2018).
Read the Tirzepatide report →Autophagy supports neural maintenance, but verified human neuroplasticity evidence is not clean.
Read the Spermidine report →Preclinical neurotrophic-pathway data and BBB penetration are interesting, but human neuroplasticity endpoints are limited.
Read the Astaxanthin report →Animal neurogenesis pathways exist, but human neuroplasticity endpoints are not established. Keep this exploratory and do not treat thymosin alpha-1 as a cognitive-enhancement peptide.
Read the Thymosin Alpha-1 report →BDNF data support a neuroplasticity hypothesis. Inozemtseva 2008 reported hippocampal BDNF-expression effects after intranasal Selank in rats, but no human neuroplasticity endpoint exists.
Read the Selank report →DHA supports neuronal membrane structure, but clinical neuroplasticity outcomes remain limited and not practice-changing.
Read the Omega-3 report →Androgens influence brain biology, but human neuroplasticity outcomes from TRT are not established. The null T Trials cognition result keeps the score low despite mechanistic interest.
Read the TRT (Testosterone Replacement Therapy) report →Glutamate modulation is mechanistically relevant, but human neuroplasticity endpoints are absent. Stays preclinical.
Read the NAC (N-Acetylcysteine) report →Preclinical BDNF-related evidence exists, but human neuroplasticity evidence is thin.
Read the L-Theanine report →Nerve growth factor interactions; limited direct evidence. Preclinical nerve repair does not establish broad cognitive or skill-learning plasticity.
Read the BPC-157 report →Novel motor patterns and involuntary recruitment may challenge cortical control, especially in rehab. Direct neuroplasticity endpoints are sparse, so WB-EMS should be framed as motor re-education support, not a brain-training technology.
Read the Full-Body EMS report →No direct human neuroplasticity evidence was identified. Tongkat Ali should not be framed as a brain-rewiring or learning-enhancement supplement.
Read the Tongkat Ali report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Bromantane and semax tie at 7.1, and they are the only two in this category scored strong recommend. Selank is third at 6.9 if anxiety rather than focus…
Bromantane, for anything you plan to repeat. It scores 7.1 against phenylpiracetam's 5.5 and wins every shared use case that is not a floor tie: energy 6.2 to…
Cerebrolysin scores 6.3 and P-21 scores 5.0, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.9 and dihexa 4.4, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5 against pinealon's 1.7, because it acts on the pineal gland and melatonin output while pinealon is a…
Semax scores 7.1 and cerebrolysin 6.3. Semax wins cognition, neuroplasticity and nerve regeneration, costs an ESTIMATED $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.1 against dihexa's 4.4, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
Neurofeedback, at 8.3 out of 10 for neuroplasticity. For neuroplasticity, Neurofeedback lands at 8.3/10 because Ostinelli et al.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5 out of 10 for neuroplasticity.
Dihexa scores 5.0 out of 10 for neuroplasticity but only 4.4 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
34 of the 78 interventions evaluated for neuroplasticity score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
